Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Summary

This study is a single-arm, phase I trial, up to 16 participants with resectable PDA. The study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with standard-of-care mFOLFIRINOX in the neoadjuvant setting.

Timeline

Start

2022-09-08

Primary completion

2026-07-15

Completion

2026-12-31

Publications

• Zarei M, Hajihassani O, Hue JJ, Graor HJ, Rothermel LD, Winter JM. Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer. bioRxiv [Preprint]. 2023 Mar 29:2023.03.29.534596. doi: 10.1101/2023.03.29.534596.

Drugs

Indications